溶小體儲積症治療市場：依療法、適應症、最終使用者和地區分類

Lysosomal Storage Diseases Therapeutics Market, By Treatment, By Indication, By End User, and By Region

出版日期: 2026年04月27日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

溶小體儲積症治療市場預計在 2026 年達到 126 億美元，預計到 2033 年將達到 224.4 億美元。預計從 2026 年到 2033 年，該市場將以 8.6% 的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	126億美元
歷史數據時期：	2020-2024	預測期：	2026-2033
2026年至2033年預測期間的複合年成長率：	8.60%	2033年市場規模預測：	224.4億美元

溶小體儲積症（LSDs）是由單一基因缺陷引起的疾病。約70%的LSDs是由酵素缺陷造成的，其餘則是由酵素活化劑或相關蛋白的缺陷造成的。位於特定染色體位點的基因編碼特定的酶，酶編碼過程的異常會導致產生惰性的酶。同樣，活化劑缺陷是由活化劑基因的突變引起的。這些異常會導致酵素在器官中積聚，從而引發疾病，並決定臨床徵兆和症狀。嬰兒童的症狀往往比成人嚴重。即使是同一種疾病，兒童和成人的臨床特徵也常常有所不同。例如，兒童發育中的大腦更容易受到損傷，導致功能障礙的症狀和體徵，而成人的症狀和體徵可能較輕或沒有。酵素檢測通常是首選的診斷方法，但基因突變的遺傳分析可以提高診斷的準確性。目前有很多針對這些疾病的現代治療方法。在器官損傷加重之前儘早應用這些治療方法，可望預防或延緩疾病的進展，提高生活品質，延長壽命。

市場動態

溶小體儲積症日益受到重視、政府進行宣傳活動以及新產品的上市，都推動了全球溶小體儲積症治療市場的成長。例如，2023年5月11日，美國製藥公司Chiesi USA, Inc.宣布其產品「Elfabrio」已獲得美國食品藥物管理局（FDA）的批准。本產品採用培尼加糖苷酶α進行酵素替代療法（ERT），用於治療法布瑞氏症成人患者。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數對全球溶小體儲積症治療市場的主要參與者進行了分析：公司概況、產品系列、主要亮點、財務績效和策略。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
全球溶小體儲積症治療市場報告的目標對象包括該行業的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用分析全球溶小體儲積症治療市場中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

Shire plc
Pfizer, Inc.
Sanofi SA
BioMarin Pharmaceutical Inc
Actelion Ltd.
Raptor Pharmaceutical Corp
Protalix BIoTherapeutics Inc.
Amicus Therapeutics, Inc.

第9章

調查方法
關於本公司

簡介目錄

Product Code: CMI3651

Lysosomal Storage Diseases Therapeutics Market is estimated to be valued at USD 12.60 Bn in 2026 and is expected to reach USD 22.44 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.6% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 12.60 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	8.60%	2033 Value Projection:	USD 22.44 Bn

Lysosomal storage diseases (LSDs) are diseases caused by defects in single-genes. Enzyme defects cause nearly seventy percent of the LSDs, and the rest are defects in enzyme activator or associated proteins. A gene on a particular chromosome locus transcribes a particular enzyme, improper enzyme-coding results in inactive enzymes. Similarly, defective activators result from mutations in activator genes. These conditions cause disease of the organs in which they accumulate and decide the clinical signs and symptoms. Infants and children suffer more severely compared to adults. The clinical features are unique in many children and adults for the same disease. For example, the child's developing brain is more susceptible to insults and manifests symptoms and signs of dysfunction, while this may be milder or absent in adults. Enzyme testing is usually the initial diagnostic test, but genetic analysis of the gene mutations adds precision. There are many modern therapeutic techniques for these conditions. When applied early before organ damage sets in, these therapies have the potential to prevent or delay damage, improve quality of life, and increase lifespan.

Market Dynamics

Increasing significance of lysosomal storage diseases, arrangement of awareness programs by governments and the launch of new products are attributed to the growth of the global lysosomal storage diseases therapeutics market. For instance, on May 11, 2023, Chiesi USA, Inc., a U.S. based pharmaceutical company announced that its product Elfabrio was approved by U.S. Food and Drug Administration. It uses the enzyme pegunigalsidase alfa for enzyme replacement therapy (ERT) to treat adults with confirmed Fabry disease.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global lysosomal storage diseases therapeutics market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Shire plc, Pfizer, Inc., Sanofi, BioMarin Pharmaceutical Inc., Actelion Ltd., Raptor Pharmaceutical Corp., Protalix Biotherapeutics Inc., Quest Diagnostics, and Amicus Therapeutics, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global lysosomal storage diseases therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lysosomal storage diseases therapeutics market.

Detailed Segmentation:

Global Lysosomal Storage Diseases Therapeutics Market, By Treatment (Revenue, USD Bn, 2021 - 2033)
Enzyme Replacement Therapy
Stem Cell Therapy
Substrate Reduction Therapy
Others
Global Lysosomal Storage Diseases Therapeutics Market, By Indication (Revenue, USD Bn, 2021 - 2033)
Gaucher's Disease
Fabry Disease
Pompe's Syndrome
Mucopolysaccharidosis
Others
Global Lysosomal Storage Diseases Therapeutics Market, By End User (Revenue, USD Bn, 2021 - 2033)
Hospitals
Clinics
Global Lysosomal Storage Diseases Therapeutics Market, By Geography (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Middle East:
- GCC
- Israel
- Rest of Middle East
Africa
- Central Africa
- South Africa
- North Africa
Company Profiles
Shire plc
Pfizer, Inc.
Sanofi SA
BioMarin Pharmaceutical Inc
Actelion Ltd.
Raptor Pharmaceutical Corp.
Protalix Biotherapeutics Inc.
Amicus Therapeutics, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Treatment
- Market Snapshot, By Indication
- Market Snapshot, By End user
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Lysosomal Storage Diseases Therapeutics Market, By Treatment, 2021-2033, (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 -2033
- Segment Trends
Enzyme Replacement Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Stem Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Substrate Reduction Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)

5. Global Lysosomal Storage Diseases Therapeutics Market, By Indication, 2021-2033, (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 -2033
- Segment Trends
Gaucher's Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Fabry Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Pompe's Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Mucopolysaccharidosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)

6. Global Lysosomal Storage Diseases Therapeutics Market, By End user, 2021-2033, (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 -2033
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)

7. Global Lysosomal Storage Diseases Therapeutics Market, By Region, 2021-2033, (US$ Billion)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022 -2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication , 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Billion)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Billion)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Billion)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Shire plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sanofi SA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
BioMarin Pharmaceutical Inc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Actelion Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Raptor Pharmaceutical Corp
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Protalix Biotherapeutics Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Amicus Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies